| ²é¿´: 799 | »Ø¸´: 1 | |||
| ±¾Ìû²úÉú 1 ¸ö ·ÒëEPI £¬µã»÷ÕâÀï½øÐв鿴 | |||
[½»Á÷]
Informative diagnostics for personalized medicine
|
|||
|
Sample TextSample TextSample Text Upstream of an in vitro diagnostic platform, there are outstanding opportunities for chemical biologists to both identify and create affinity recognition strategies for disease biomarkers, which may be discovered at the genomic, transcriptomic, proteomic or metabolomic levels. In the clinic, informative biomarkers may be used in many ways13, including as preclinical diagnostic biomarkers for presymptomatic detection, prognostic biomarkers, which forecast disease progression, and theragnostic biomarkers, which suggest the most appropriate treatment strategy, such as Her2 in the case of trastuzumab. |
» ²ÂÄãϲ»¶
ÊÛSCIÒ»ÇøÎÄÕ£¬ÎÒ:8.O.551.O.5.4,¿ÆÄ¿È«,¿ÉÙ¤¼±
ÒѾÓÐ8È˻ظ´
ÊÛSCIÒ»ÇøÎÄÕ£¬ÎÒ:8.O.55.1.O.54,¿ÆÄ¿ÆëÈ«,¿ÉÙ¤¼±
ÒѾÓÐ3È˻ظ´
Ã÷ÌìÓ¦¸Ã¿É²éÁË£¡£¿
ÒѾÓÐ5È˻ظ´
Èç¹û´Ë¿ÌÄãÕýÔÚΪ¹ú»ù¸Ðµ½½¹ÂÇ£¬²»·ÁÀ´ÌýÌýÕâÊס¶»ù½ðÖ®Íâ¡·
ÒѾÓÐ7È˻ظ´
ûÓÐÈκÎÏûÏ¢-ÊDz»ÊǾÍÁ¹ÁË
ÒѾÓÐ8È˻ظ´
ÊÛSCI-T0PÎÄÕ£¬ÎÒ:8O.5.5.1.O.54,¿ÆÄ¿ÆëÈ«,¿É+¼±
ÒѾÓÐ3È˻ظ´
ÈËÆø²»ÐÐÁË
ÒѾÓÐ10È˻ظ´
ÎÒÃæÉÏÍêµ°ÁË
ÒѾÓÐ10È˻ظ´
ÄÜ·ñÍ˳ö²ÎÓëµÄÃæÉÏÏîÄ¿½â³ýÏÞÏî
ÒѾÓÐ24È˻ظ´
filecode£¬4¸öjtjcÁË
ÒѾÓÐ17È˻ظ´
petrocatal
ľ³æ (ÕýʽдÊÖ)
- ·ÒëEPI: 134
- Ó¦Öú: 23 (СѧÉú)
- ¹ó±ö: 0.01
- ½ð±Ò: 3436.6
- Ìû×Ó: 959
- ÔÚÏß: 299.5Сʱ
- ³æºÅ: 557856
ÓÚÌï9858(½ð±Ò+5, ·ÒëEPI+1):лл£¡»¹ÓÐÄØ£¬ÄÜÔÙ°ïÎÒ·ÒëÒ»ÏÂÆäËûµÄÂð 2010-12-05 20:02:50
|
¿ÉΪ¸öÐÔ»¯Ò½Ñ§ÌṩÏà¹ØÐÅÏ¢µÄÕï¶Ï ÔÚÉúÎïÌåÕï¶Ïƽ̨µÄÉÏÓΣ¬ÔÚȾɫÌå×é¡¢·Â¼±¾ÒÔ¼°Ð³´úлˮƽÉÏ£¬ÉúÎﻯѧ¼ÒÓкܺõĻú»áÀ´Ö¤ÊµÓëÓÃÓÚ¼²²¡µÄÉúÎï±ê¼ÇµÄÀàͬÐÔʶ±ð²ßÂÔ¡£ÔÚÖÎÁƹý³ÌÖУ¬ÉúÎï±ê¼ÇÎï¿ÉÌṩÏà¹ØÐÅÏ¢²¢ÓкܶàÀûÓ÷½Ê½£¬°üÀ¨×÷ΪǰÆÚÖÎÁÆ¡¢Õï¶ÏÐÔµÄÉúÎï±ê¼ÇÎï¿ÉÓÃÓÚǰÆÚÖ¢×´µÄ¼ì²â£¬Ô¤Õ×ÐÔµÄÉúÎï±ê¼Ç¿ÉÒÔÔ¤²â¼²²¡µÄ·¢Õ¹£¬theragnostic ÉúÎï±ê¼Ç¿É¶ÔÖÎÁÆÌṩ×îºÏÊʲßÐÔÂÔ½¨Ò飬ÈçHer2ÓÃÓÚÇúÍ×Öéµ¥¿¹ÖС£ |
2Â¥2010-11-28 21:08:14









»Ø¸´´ËÂ¥
20